S. Kalsoom, Ammara Zamir, A. Rehman
Aug 30, 2022
Citations
0
Influential Citations
3
Citations
Quality indicators
Journal
Journal of Clinical Pharmacy and Therapeutics
Abstract
Nadolol is a non‐selective beta‐adrenergic antagonist that is used for the treatment of hypertension and angina. The primary route for its administration is oral. It is given once daily as it has a longer half‐life (t½). The purpose of conducting this systematic review is to provide a comprehensive view of all the available pharmacokinetic (PK) data on nadolol in humans. This review aimed to systematically collate and analyze publish data on the clinical PK of nadolol in humans and this can be beneficial for the clinicians in dosage adjustments.